INVA
Innoviva Inc
$
22.260
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
22.265
Open
22.200
VWAP
22.06
Vol
151.38K
Mkt Cap
1.66B
Low
21.820
Amount
3.34M
EV/EBITDA(TTM)
6.65
Total Shares
62.44M
EV
1.38B
EV/OCF(TTM)
6.86
P/S(TTM)
4.85
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
99.97M
+8.89%
--
--
91.30M
+2.01%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Innoviva, Inc. (INVA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.61%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+6.61%
In Past 3 Month
4 Analyst Rating
70.71% Upside
Wall Street analysts forecast INVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INVA is 38.00 USD with a low forecast of 17.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
1 Sell
Moderate Buy
70.71% Upside
Current: 22.260
Low
17.00
Averages
38.00
High
55.00
70.71% Upside
Current: 22.260
Low
17.00
Averages
38.00
High
55.00
Goldman Sachs
Sell
initiated
$17
2025-09-30
Reason
Goldman Sachs
Price Target
$17
2025-09-30
initiated
Sell
Reason
Goldman Sachs initiated coverage of Innoviva with a Sell rating and $17 price target. The stock's recent rally has raised the bar for the company's infectious disease platform platform going forward, the analyst tells investors in a research note. The firm believes Innoviva's 2031 royalty-related patent cliff will start to weigh on the stock's performance in 2026.
H.C. Wainwright
Raghuram Selvaraju
Buy
upgrade
$40 -> $45
2025-08-11
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$40 -> $45
2025-08-11
upgrade
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Innoviva to $45 from $40 and keeps a Buy rating on the shares. The company's Q2 revenue and earnings outperformed expectations, the analyst tells investors in a research note.
Oppenheimer
Outperform
initiated
$35
2025-08-11
Reason
Oppenheimer
Price Target
$35
2025-08-11
initiated
Outperform
Reason
Oppenheimer initiated coverage of Innoviva with an Outperform rating and $35 price target. Innoviva is a holding company comprised of royalty distributions from Breo and Anoro, a specialty therapeutics unit with assets for treating acute critical care, and a strategic finance equity investments arm, the analyst tells investors in a research note. The firm believes the company's specialty therapeutics and royalty commercial results will drive share outperformance.
H.C. Wainwright
H.C. Wainwright
initiated
$40
2025-07-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$40
2025-07-14
initiated
Reason
H.C. Wainwright initiated coverage of Innoviva with a Buy rating and $40 price target. The firm says Innoviva is a diversified company marketing multiple commercial products that is benefiting from "durable" royalty streams on mass market respiratory disease franchises.
Cantor Fitzgerald
NULL -> Overweight
initiated
$26
2025-07-11
Reason
Cantor Fitzgerald
Price Target
$26
2025-07-11
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of Innoviva with an Overweight rating and $26 price target.
Scotiabank
Louise Chen
Buy
Initiates
$55
2025-03-07
Reason
Scotiabank
Louise Chen
Price Target
$55
2025-03-07
Initiates
Buy
Reason
Scotiabank initiated coverage of Innoviva with an Outperform rating and $55 price target. Innoviva's stock has been overlooked because its value proposition is not explicitly clear, but bolder moves to maximize shareholder value could be coming, including new launches, expanding the Innoviva Specialty Therapeutics platform, and monetizing non-core assets, the analyst tells investors in a research note. The stock also looks interesting in a tough capital markets environment because it is profitable and has historically been successful at consolidating undervalued assets, the firm argues.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Innoviva Inc (INVA.O) is 12.33, compared to its 5-year average forward P/E of 11.73. For a more detailed relative valuation and DCF analysis to assess Innoviva Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
11.73
Current PE
12.33
Overvalued PE
17.89
Undervalued PE
5.57
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
7.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.84
Undervalued EV/EBITDA
4.63
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Overvalued
5Y Average PS
3.64
Current PS
22.20
Overvalued PS
5.46
Undervalued PS
1.82
Financials
Annual
Quarterly
FY2025Q3
YoY :
+20.44%
107.80M
Total Revenue
FY2025Q3
YoY :
-20.03%
34.58M
Operating Profit
FY2025Q3
YoY :
+7312.04%
89.91M
Net Income after Tax
FY2025Q3
YoY :
+5200.00%
1.06
EPS - Diluted
FY2025Q3
YoY :
-18.96%
39.24M
Free Cash Flow
FY2025Q3
YoY :
-14.09%
70.07
Gross Profit Margin - %
FY2025Q3
YoY :
+4.69%
48.17
FCF Margin - %
FY2025Q3
YoY :
+6032.35%
83.40
Net Margin - %
FY2025Q3
YoY :
+81.70%
12.41
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
28.4M
USD
3
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
450.0K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
28.4M
USD
3
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
INVA News & Events
Events Timeline
2025-11-05 (ET)
2025-11-05
16:32:30
Innoviva Board Approves $125 Million Stock Buyback Plan
2025-11-05
16:32:05
Innoviva announces Q3 earnings per share of $1.08 compared to 2 cents in the same period last year.
2025-06-12 (ET)
2025-06-12
07:18:48
Innoviva announces zoliflodacin NDA granted Priority Review by FDA
Sign Up For More Events
Sign Up For More Events
News
4.0
11-06BenzingaCantor Fitzgerald Keeps Overweight Rating on Innoviva, Increases Price Target to $31
9.5
11-06NASDAQ.COMInnoviva, Inc. Announces Rise in Q3 Earnings
4.0
09-30BenzingaIn-Depth Insights: 5 Analysts Weigh in on Innoviva Stock
Sign Up For More News
People Also Watch
AKO.A
Embotelladora Andina SA
22.440
USD
+2.00%
XRX
Xerox Holdings Corp
2.750
USD
-3.17%
COMM
CommScope Holding Company Inc
17.050
USD
+1.91%
SBH
Sally Beauty Holdings Inc
13.740
USD
-4.91%
CDNA
CareDx Inc
15.990
USD
+0.76%
CIM
Chimera Investment Corp
11.910
USD
-1.16%
ULH
Universal Logistics Holdings Inc
14.310
USD
-2.12%
NVGS
Navigator Holdings Ltd
17.560
USD
+0.11%
PFBC
Preferred Bank
91.550
USD
-0.35%
ECPG
Encore Capital Group Inc
49.340
USD
+1.04%
FAQ
What is Innoviva Inc (INVA) stock price today?
The current price of INVA is 22.26 USD — it has increased 0.27 % in the last trading day.
What is Innoviva Inc (INVA)'s business?
What is the price predicton of INVA Stock?
What is Innoviva Inc (INVA)'s revenue for the last quarter?
What is Innoviva Inc (INVA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Innoviva Inc (INVA)'s fundamentals?
How many employees does Innoviva Inc (INVA). have?